Thoracic Oncology, Chief of Heme/Onc @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, #DCLung26 #TexasLung27 #HereWeGo #LetsGoBucs
Joined September 2011
- Tweets 22,777
- Following 3,566
- Followers 30,016
- Likes 108,449
7,620 Photos and videos
Pinned Tweet
Apr 16
Registration is open for #DCLung26 on 10/10/26 - with 77 expert multi-disciplinary faculty from the US & abroad, this will be our biggest yet! Everything lung cancer related in this one-day, multi-disciplinary CME conference in downtown Washington DC!
medstarhealth.org/dclung
1
13
38
5,716
Stephen V Liu, MD retweeted
13h
Future of hematology/oncology - it has been an honor to support their journey and help them reach this finish line in training. Wishing them all the best in this new chapter of life and career.
@LombardiCancer @StephenVLiu @GeorgetownHOF
2
3
18
959
📣 The IASLC Women in #ThoracicOncology Task Force survey is still open.
If you're a woman working in thoracic oncology, we want to hear about your experiences, perspectives, and priorities. Your feedback will help guide future initiatives to support women across the field.
Take the survey: bit.ly/4uAPNwd
#WomenInMedicine
4
8
803
Jun 13
Integrated molecular and clinical analysis of thymic epithelial tumors reported @JCOPO_ASCO led by Dr. @chulkimMD - explains key differences between thymic carcinoma and thymoma and highlights targeting MTAP deletions as a potential viable strategy
ascopubs.org/doi/10.1200/PO-…
8
16
1,536
Stephen V Liu, MD retweeted
DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers - Final results (full access link below) thanks to all esp the patients involved in the 1st NCI rare tumor IO basket study! sciencedirect.com/science/ar…
3
7
21
13,756
📆 Early Bird registration for #WCLC26 ends tomorrow!
Register by June 12 to save up to $500. IASLC Members can save up to $750 total.
Register now: bit.ly/wclcreg26
5
8
995
Jun 11
GSK acquires Nuvalent for $10.6 billion ahead of new ROS1 TKI (zidesamtinib), ALK TKI (neladalkib) and investigational HER2 TKI (NVL-330).
reuters.com/business/healthc…
1
12
40
4,107
🎧 In Part 2 of the #ASCO26 Highlights series, @NarjustFlorezMD and @StephenVLiu are joined by Dr. Julie R. Brahmer and @peters_solange to discuss key immunotherapy advances presented at the 2026 @ASCO Annual Meeting.
The episode covers emerging data on PD-1/VEGF and PD-L1/VEGF bispecific antibodies, ADC-immunotherapy combinations, and promising new strategies for #KRAS-mutant lung cancers.
Listen now : bit.ly/4uZjt6o
#LungCancer #LungCancerConsidered
9
17
1,508
Jun 11
Early morning learning from Dr. @ZPiotrowskaMD discussing new standards of care for HER2 mutant NSCLC. HER2 ADCs like T-DXd giving way in the first line setting to TKIs like zongertinib - but will the future for advanced HER2 NSCLC be combinations?
3
12
49
3,123
Ready to help shape the future of #WCLC28?
IASLC is accepting applications for 2028 World Conference on Lung Cancer Co-Chairs. Lead scientific discussions, foster global collaboration, and help guide the world's largest thoracic oncology meeting in Copenhagen, Denmark.
Apply today: bit.ly/4oe7a3i
#IASLC #LungCancer #ThoracicOncology
1
6
24
1,931
In this episode of the @IASLC podcast, Lung Cancer Considered, Dr. @NarjustFlorezMD & I discuss #ASCO26 immunotherapy highlights with Dr. Julie Brahmer & Dr. @peters_solange, focusing on bispecifics ivonescimab (HARMONi-6) and pumitamig, ADCs, and KRAS.
iaslc.org/iaslc-news/lung-ca…
5
14
42
3,136
Stephen V Liu, MD retweeted
Jun 9
Our paper on integrated molecular profiling of thymic epithelial tumors (TETs) is now out in @JCOPO_ASCO!
We analyzed 138 TET samples using whole-exome whole-transcriptome sequencing to map the genomic landscape of thymomas and thymic carcinoma (TC).
bit.ly/4vCXd1X
9
22
78
7,120
Stephen V Liu, MD retweeted
Jun 9
The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO shorturl.at/GzAe2, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial shorturl.at/26apO @TROGfightcancer @TOGAANZ to answer this question! #radonc
6
68
139
9,119
Stephen V Liu, MD retweeted
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee - Journal of Thoracic Oncology jto.org/article/S1556-0864(2…
31
66
8,566
Real world outcomes from German MesoNet with 2L platinum pemetrexed after 1L nivolumab ipilimumab for pleural mesothelioma @ClinicalLung. mPFS 5.8m, mOS 11.5m, RR 28%, DCR 72% with better OS in non-epithelioid. Attrition: only 16% of pts get 3L tx.
clinical-lung-cancer.com/art…
1
12
29
2,524
Planning to attend #WCLC26? Don't miss your chance to save.
Early Bird registration ends June 12.
Join colleagues from around the world in Seoul for groundbreaking science, global collaboration, and hundreds of sessions spanning the full spectrum of thoracic oncology.
Register today: bit.ly/wclcreg26
9
19
5,512
Details on safety of consolidation osimertinib after chemoradiation for EGFR mutant NSCLC from the phase III LAURA trial. Radiation pneumonitis seen in 48% with osi and 38% with placebo, mostly low grade, 87% continued osi, 93% without recurrence.
lungcancerjournal.info/artic…
2
17
45
4,053
Quite a whirlwind at #ASCO26 with lung cancer updates. For highlights from targeted therapy, Dr. @NarjustFlorezMD and I spoke with Drs. Alice Shaw and Jonathan Goldman for the @IASLC podcast, Lung Cancer Considered. Listen today! #ALK #RET #EGFR
iaslc.org/iaslc-news/lung-ca…
3
22
51
5,403